Abiopharma

🔍 Shachar Erez (Executive)

Company: Talkspace, Inc. (TALK)

Report Date: 2026-08-17

Detailed Transactions and Holdings:

• Sold 355,420 shares of Common Stock (Direct)
  Date: 2026-08-17 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1
• Sold 71,646 shares of Common Stock (Direct)
  Date: 2026-08-17 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1
• Sold 8,573,437 shares of Common Stock (Direct)
  Date: 2026-08-17 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 63,402 shares of Stock Options at $8.52 per share (Derivative)
  Date: 2026-08-17 | Code: D | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1

Footnotes:

• F1: In connection with the terms of that certain Agreement and Plan of Merger, dated as of March 9, 2026 (the "Merger Agreement"), by and among Talkspace, Inc., a Delaware Corporation (the "Issuer"), Universal Health Services, Inc., a Delaware corporation ("Parent"), and UHS Merger Subsidiary, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as an indirect wholly owned subsidiary of Parent at the effective time of the Merger (the "Effective Time").
• F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding share of Issuer common stock, par value $0.0001 per share ("Common Stock") (other than shares of Common Stock canceled pursuant to the Merger Agreement) was converted into the right to receive $5.25 in cash (the "Merger Consideration").
• F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer restricted stock unit that was or became vested in accordance with its terms at the Effective Time (each, a "Vested RSU") was canceled and converted into the right to receive a cash payment equal to the product of (i) the number of shares of Common Stock subject to such Vested RSU immediately prior to the Effective Time and (ii) the Merger Consideration.
• F4: Qumra Capital GP II, L.P. ("Qumra GP II") is the general partner of Qumra Capital II, L.P ("Qumra II") and Qumra Capital Israel I Ltd. ("Qumra Capital Israel I") is the general partner of Qumra GP II. Mr. Shachar is a managing partner of Qumra Capital Israel I and disclaims beneficial ownership of the shares held of record by Qumra II except to the extent of his pecuniary interest therein.
• F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer stock option that was or became vested in accordance with its terms at the Effective Time reported in this row had an exercise price equal to or greater than the Merger Consideration and was canceled for no consideration.